August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Howard McLeod Highlighted The Results of the Phase II Randomized LEANOX Trial
Aug 10, 2025, 05:10

Howard McLeod Highlighted The Results of the Phase II Randomized LEANOX Trial

Howard McLeod, Center Director at Center for Precision Medicine & Functional Genomics, shared a post on LinkedIn:

“Details matter in cancer therapy! Use of lean body mass, rather then total body mass, for Oxalaplatin chemotherapy resulted in similar relapse free survival, but much less peripheral neuropathy! Precision oncology doesn’t just mean fancy genomics or such.”

Title: Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial

Authors: Eric Assenat, Meher Ben Abdelghani, Sophie Gourgou, Hervé Perrier, Faiza Khemissa Akouz, Romain Desgrippes, Marie-Pierre Galais, Chloé Janiszewski, Thibault Mazard, Yves Rinaldi, Côme Lepage, Raphael Tetreau, Pierre Senesse

Read the Full Article.

Howard McLeod

Read more posts on Colon Cancer.